Brainstorm Cell Therapeutics(BCLI)
搜索文档
Brainstorm Cell Therapeutics(BCLI) - 2019 Q3 - Earnings Call Transcript
2019-11-15 02:51
BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) Q3 2019 Earnings Conference Call November 14, 2019 8:00 AM ET Company Participants Sean Leous – ICR Westwicke Chaim Lebovits – President and Chief Executive Officer Preetam Shah – Chief Financial Officer Ralph Kern – Chief Operating Officer, Chief Medical Officer Arturo Araya – Chief Commercial Officer Conference Call Participants David Bautz – Zacks Small Cap Research Jason Kolbert – Dawson James Jack Mayer – Private Investor Jason McCarthy – Maxim Operator ...
Brainstorm Cell Therapeutics(BCLI) - 2019 Q3 - Quarterly Report
2019-11-14 19:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Dela ...
Brainstorm Cell Therapeutics(BCLI) - 2019 Q2 - Earnings Call Transcript
2019-08-14 01:31
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q2 2019 Results Earnings Conference Call August 13, 2019 8:00 AM ET Company Participants Sean Leous - ICR Westwicke Chaim Lebovits - President and Chief Executive Officer Eyal Rubin - Executive Vice President and Chief Financial Officer Ralph Kern - Chief Operating Officer and Chief Medical Officer Conference Call Participants David Bautz - Zacks Small Cap Research Jason Kolbert - Dawson James John Rice - Wells Fargo Operator Good day and welcome to BrainStorm ...
Brainstorm Cell Therapeutics(BCLI) - 2019 Q2 - Quarterly Report
2019-08-13 18:03
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.00005 par value BCLI NASDAQ Stock Market LLC (Nasdaq Capital Market) FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period f ...
Brainstorm Cell Therapeutics(BCLI) - 2019 Q1 - Quarterly Report
2019-05-11 05:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware ...
Brainstorm Cell Therapeutics(BCLI) - 2018 Q4 - Annual Report
2019-03-30 05:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2018 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM __________ TO __________ COMMISSION FILE NUMBER 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact Name of Registrant as specified in its charter) Delaware 20-7273918 (State or other jurisd ...